Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

“…<div><p>Every 15 minutes in the US, an infant exposed to opioids is born. Approximately 50% of these newborns will develop Neonatal Opioid Withdrawal Syndrome (NOWS) within 5 days of birth. …”

Protocol measures. by Sarah E. Maylott (14560785)

“…<div><p>Every 15 minutes in the US, an infant exposed to opioids is born. Approximately 50% of these newborns will develop Neonatal Opioid Withdrawal Syndrome (NOWS) within 5 days of birth. …”

Cry variables. by Sarah E. Maylott (14560785)

“…<div><p>Every 15 minutes in the US, an infant exposed to opioids is born. Approximately 50% of these newborns will develop Neonatal Opioid Withdrawal Syndrome (NOWS) within 5 days of birth. …”

Summary of five key points guiding the Safe Steps evaluation and implementation. by Esario IV Daguman (21474116)

Table_5_Structurally rich dry grasslands – Potential stepping stones for bats in open farmland.docx by Sophie P. Ewert (14512787)

Table_5_Structurally rich dry grasslands – Potential stepping stones for bats in open farmland.docx by Sophie P. Ewert (14512787)

Competition localization increases with growth rate or the distances between colonies, and decreases with the resource diffusion constant. by Jeremy M. Chacón (8259792)

Untargeted metabolomic analysis of delayed death-parasites indicates isoprenoid defect and decreased haemoglobin turnover. by Kit Kennedy (4915510)

Decreasing fluconazole susceptibility of clinical South African <i>Cryptococcus neoformans</i> isolates over a decade by Serisha D. Naicker (8648370)

Retinoic acid decreases intracellular K⁺ in pectoral fin buds via transcriptional activation of the calcineurin inhibitor <i>rcan2</i>. by Xiaowen Jiang (8291814)

Trace-weighted images at b = 50 s/mm². by Tobit Führes (12647099)

Flow chart of the study procedures. by Kazuhiko Ikeuchi (9234268)

“…Pre-treatment spontaneous decrease of RPR titer was associated with a slower decrease in post-treatment RPR titer.…”

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

LBM-based approach using synchronous transformation with a time step of 0.43s, PNGM-based method using asynchronous transformation with a 5s time step, VGA using explicit scheme wi... by Mouad Klai (20818364)

EB (Ethyl Butyrate) as a Cosolvent of Electrolyte Tuning an Ultrathin CEI Membrane for Improving the Ultralow-Temperature Behaviors of LiNi_0.8Co_0.1Mn<sub>0.1<... by Lucheng Li (13753395)

Subjects:

EB (Ethyl Butyrate) as a Cosolvent of Electrolyte Tuning an Ultrathin CEI Membrane for Improving the Ultralow-Temperature Behaviors of LiNi_0.8Co_0.1Mn<sub>0.1<... by Lucheng Li (13753395)

Subjects:

Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

Subjects:

Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

Subjects:

Repeated LSPC treatment prolongs survival of and decreases PrP^Res accumulation in a subset of prion-infected mice. by Heather Bender (363996)

Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

“…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”